



CORPORATE OVERVIEW MARCH 2020

Disclaimer

This presentation is made by Applied Therapeutics, Inc. (the “Company”). Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or the Company or any director, employee, agent, or adviser of the Company. This presentation does not purport to be all-inclusive or to contain all of the information you may desire. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy the Company's securities, nor shall there be any sale of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Various statements in this presentation concerning the Company's future expectations, plans and prospects, including without limitation, the Company's current expectations regarding its strategy, its product candidate selection and development timing, its management team capabilities, and the ability of the Company's product candidates to have a clinically meaningful effect on the target patient populations, constitute forward-looking statements. The use of words such as “may,” “might,” “will,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “future,” “potential,” or “continue,” the negative of these and other similar expressions are intended to identify such forward looking statements. Such statements, based as they are on the current analysis and expectations of management, inherently involve numerous risks and uncertainties, known and unknown, many of which are beyond the Company's control. Such risks include, but are not limited to: the impact of general economic conditions, general conditions in the biopharmaceutical industries, changes in the global and regional regulatory environments in the jurisdictions in which the Company does or plans to do business, market volatility, fluctuations in costs and changes to the competitive environment. Consequently, actual future results may differ materially from the anticipated results expressed in the forward-looking statements. In the case of forward-looking statements regarding investigational product candidates and continuing further development efforts, specific risks which could cause actual results to differ materially from the Company's current analysis and expectations include: failure to demonstrate the safety, tolerability and efficacy of our product candidates; final and quality controlled verification of data and the related analyses; the expense and uncertainty of obtaining regulatory approval, including from the U.S. Food and Drug Administration and European Medicines Agency; the possibility of having to conduct additional clinical trials and our reliance on third parties such as our licensors and collaboration partners regarding our suite of technologies and product candidates. Further, even if regulatory approval is obtained, biopharmaceutical products are generally subject to stringent on-going governmental regulation, challenges in gaining market acceptance and competition.

These risks and uncertainties are described more fully under the caption “Risk Factors” in the Company's filings with the Securities and Exchange Commission. Other risks and uncertainties of which the Company is not currently aware may also affect Company's forward-looking statements. The reader should not place undue reliance on any forward-looking statements included in this presentation. These statements speak only as of the date made and the Company is under no obligation and disavows any obligation to update or revise such statements as a result of any event, circumstances or otherwise, unless required by applicable legislation or regulation.

Investment Highlights



2 Pivotal programs in high unmet need indications with near-term milestones

- Positive topline Galactosemia data announced January 2020; NDA expected 2H20
- Diabetic Cardiomyopathy pivotal data 2021



Distinct late-stage commercial opportunities

- Galactosemia - easily commercialized orphan indication based on biomarker data
- Diabetic Cardiomyopathy - potential blockbuster indication supported by deep science




Reproducible discovery and development strategy

- Early stage pipeline in orphan oncology indications targeting PI3k

Our mission is to create transformative, life-changing treatments for patients who desperately need them



Applying Science to Transform Lives



***We develop drugs quickly at a lower cost:
A significant benefit to patients in need of treatment***

Pipeline

Compound	Preclinical	Phase 1	Phase 2	Phase 3	Dosing Route	Target Tissue	Milestones
Aldose Reductase Franchise							
AT-007	Galactosemia – Pivotal Ph 2 Study				Oral	CNS	Positive topline biomarker data reported Jan 2020
AT-001	Diabetic Cardiomyopathy – Pivotal Ph 3 Study				Oral	Systemic	Ph 3 trial initiated in Q3 2019; data in 2021
AT-001	Diabetic Peripheral Neuropathy				Oral	Peripheral Nerve	
AT-001	Acute Myocardial Infarction				SC*	Systemic / Peripheral Nerve	
AT-003	Diabetic Retinopathy				Oral	Retina	Preclinical data 2019; Initiate Ph 1 2020
PI3 Kinase Franchise							
AT-104	PTCL, CTCL, TALL**				SC / Oral	Selective δ/γ inhibitor	Initiate Ph 1 2020

* Subcutaneous

** Peripheral T-cell lymphoma, cutaneous T-cell lymphoma and T-cell acute lymphoblastic leukemia

Unlocking the Potential of Aldose Reductase Inhibition

Validated Target Resistant to Therapeutic Development

- AR known to play a key role in diabetic complications and heart disease
- Past efforts failed to produce sufficiently potent, selective and tolerable drugs

Recent Advances Enable Improved ARI's

- New understanding of structural changes within the active site of AR following enzymatic activation
 - Novel structures; all drugs are new chemical entities
- Increased potency and selectivity compared to prior compounds with none of the prior off-target safety issues to date

R&D and Regulatory Opportunities

- High unmet need in numerous AR-mediated diseases
- Leverage prior ARI programs for streamlined, abbreviated development of our novel compounds
- Potential to utilize regulatory pathways designed for accelerated drug development

AT-007 for Galactosemia

AT-007 for Galactosemia

Pathogenesis of Disease

- Rare genetic metabolic disease caused by inability to break down galactose
- Galactose is a sugar produced naturally by the body
- **Aldose Reductase converts galactose to galactitol, a toxic metabolite**
- Clinical presentation:
 - Significant CNS complications - motor, speech, cognitive, and psychiatric impairments, tremor, and seizures
 - Cataracts
 - Ovarian insufficiency in females


Standard of Care

- Mandatory newborn screening and initiation of dairy free diet; dietary restriction prevents fatalities, but **does not prevent long term consequences of disease**
- No approved therapies

Galactosemia Commercial Opportunity

- **Easily identifiable patients & substantial population**
- Newborn screening and patient registry
- “Low Prevalence” but not ultra-rare
 - ~2,800 US patients; ~3,500 patients in Europe
 - ~80 new births per year in the US; more in Europe
- **Low burden of development due to biomarker-based program under new FDA guidance**
- **Opportunity to launch quickly with high market penetration**
 - >90% patients seen by ~20 specialists worldwide
 - High prescriber awareness of Applied clinical development program


Aldose Reductase Activity Causes Toxic Accumulation of Galactitol in Galactosemia



GALT Deficient Rat Model Closely Mirrors Human Disease


Biochemical Effects

GALT null rats have exponentially higher levels of galactose and galactitol, as well as Gal1p




Tissue Deposition of Galactitol

All GALT null rats display cataracts (caused by galactitol deposition in the eye) vs. none of the WT rats



CNS Outcomes


GALT null rats display deficiencies in learning, cognition, and motor skills as measured by rotarod and water maze



AT-007 Treatment Corrects All 3 Aspects of Disease in the Galactosemia Rat Model


Biochemical Effects

AT-007 treatment significantly reduced galactitol levels in all tissues without increasing galactose or Gal1p




Tissue Deposition of Galactitol

AT-007 treatment prevented galactitol accumulation in tissues, resulting in absence of cataracts




CNS Outcomes

AT-007 treatment normalized CNS outcomes on both water maze and rotarod




Galactosemia Phase 1/2 Registrational Study (ACTION-Galactosemia)

Multi-Center Placebo-Controlled Study in Healthy Volunteers & Adult Galactosemia Patients



Healthy Volunteer Endpoints:

- Safety
- Pharmacokinetics
- Pharmacodynamics



Galactosemia Endpoints:

- Safety
- Pharmacokinetics/Pharmacodynamics
- **Efficacy Biomarker - Galactitol**

Galactosemia Phase 1/2 Registrational Study (ACTION-Galactosemia)

Multi-Center Placebo-Controlled Study in Healthy Volunteers & Adult Galactosemia Patients

Healthy Volunteers

Single Ascending Dose
(n=32)

Multiple Ascending Dose
(n=32, 7 days)

Healthy Single Ascending Dose Results:

No drug-related safety issues at any dose tested

Dosing: 0.5, 5.0, 10, 20mg/kg


PK consistent with once daily dosing

(half-life ~12 hours)


Consistent exposure across patients

Linear dose response

Concentration Time Curve




Cmax



Galactosemia Phase 1/2 Registrational Study (ACTION-Galactosemia)

Multi-Center Placebo-Controlled Study in Healthy Volunteers & Adult Galactosemia Patients



AT-007 Treatment Demonstrated Robust and Sustained Reduction in Galactitol in Galactosemia Patients

- AT-007 20 mg/kg reduced plasma galactitol up to 45-54% from baseline ($p < 0.01$ vs placebo)
 - Galactitol reduction was rapid and sustained over time
 - Galactitol reduction was dose-dependent
 - 5mg AT-007 reduced plasma galactitol ~10-20% ($p > 0.05$)
- AT-007 was well tolerated
 - No drug-related adverse events noted to date in Galactosemia patients or in 72 healthy volunteers treated in Part 1 of the trial
- *Full Results from ACTION-Galactosemia at the Society for Inherited Metabolic Disorders Annual Meeting, April 26 – 29, 2020*

Further characterization of AT-007

ACTION-Galactosemia

Long-term safety in adult Galactosemia patients

Initiate pediatric study in 2020

AT-007: Oral CNS Penetrant Aldose Reductase Inhibitor

Drug Profile

- Structurally distinct molecule with potent AR inhibition and unique PK profile
- Exposure to all Galactosemia target tissues – CNS, nerve and retina penetrant
- Oral once-daily dosing (half life 12-18 hrs)

Safety

- No drug-related safety or tolerability issues in Phase 1 healthy volunteer study (SAD)
- No safety issues in newborn rat treatment studies, supporting eventual infant/pediatric use

Path to Registration

- Prevented complications of disease in Galactosemia rat model
- Biomarker effects correlate with clinical endpoints
- Did not increase galactose levels or levels of other galactose metabolites (Gal1P)
- Ongoing biomarker-based study in adults with Classic Galactosemia to read out 4Q 2019
- Pediatric study to follow

AT-001 for Diabetic Cardiomyopathy

AT-001 for Diabetic Cardiomyopathy

Pathogenesis of Disease

- Fatal fibrosis of the heart; cardiac tissue “hardens” and limits contractility
- Caused by aberrant metabolism of glucose to sorbitol in cardiomyocytes (by Aldose Reductase)
- Affects 17-24% of diabetics (77M patients worldwide)
- Occurs in both Type 1 and Type 2 diabetes

Standard of Care

- No treatments exist for DbCM
- Patients are counseled on glucose control and lifestyle

DbCM Commercial Opportunity: Blockbuster Potential with Limited Capital Requirement

Regulatory

- Clear path to registration based on functional capacity endpoint (exercise tolerance)
- Single Phase 3 trial required

Commercial Market

- 10M patients in the US; 77M worldwide
- Sufficiently narrow heart failure population - can be targeted with limited commercial investment
- High disease awareness

Point of Care

- Easily diagnosed and tracked by cardiologists (echo)
- Easily identified for referral - endocrinologists/PCPs can identify probable patients through a simple blood test (NTproBNP cardiac stress biomarker)

Strong Rationale for AT-001 Development in Diabetic Cardiomyopathy: First-in-Class Potential

Building on Prior Body of Evidence

- The role of AR in DbCM is well supported by preclinical and clinical evidence
- Proof of mechanism: Pfizer's zopolrestat achieved proof-of-concept on LVEF in Phase 2 Diabetic Cardiomyopathy trial


AT-001's Robust Pre-Clinical Profile

- 1,000X more potent than prior best-in-class ARI (zopolrestat), in vitro and in vivo
- Broad exposure: Cardiac and nerve tissue
- Highly favorable preclinical profile: MTD>2,000mg/kg

AT-001's Robust Clinical Profile (Ph 1/2 trial)

- Clinical proof-of-concept via sorbitol biomarker observed in T2D patients
- No drug related AEs observed at any dose; well tolerated
- Heart inflammatory biomarkers in 28 day arm in DbCM patients informed dose selection for pivotal study


Aldose Reductase Causes Damage to Tissues (Including Cardiomyocytes) Under Oxidative Stress



*Nf-kB is a protein complex that controls transcription of DNA, cytokine production and cell survival

Understanding Diabetic Cardiomyopathy as a Form of Heart Failure

Diabetes Stage A Heart Failure	<ul style="list-style-type: none"> • Metabolic derangement of the myocardium due to diabetes
DbCM Stage B Heart Failure	<ul style="list-style-type: none"> • Cardiac structural abnormalities • Diastolic dysfunction; LVH • Early symptoms of DbCM; noticeable impact on activities • Impaired Functional capacity (~75% normal)
Stage C Heart Failure	<ul style="list-style-type: none"> • Overt Heart Failure • HFpEF or HFrEF • Significant impact on daily activities
Stage D Heart Failure	<ul style="list-style-type: none"> • Refractory Heart Failure requiring specialized interventions (e.g. LV Assist Device) • Inability to complete daily activities



- ~24% of DbCM patients progress to overt heart failure or death within 1.5 years
- 37% within 5 years

References: Kosmala et al, JACC V O L . 6 5 , NO . 3 , 20 1 5; Swank et al. Circ HF 2012; Wang et al. JACC: Cardiovasc Imaging 2018; From et al. JACC 2010

AT-001 Phase 1/2 Trial in Type 2 Diabetic Patients

Parts A & B

Design

- 80 Type 2 Diabetic Patients
- All patients remained on concomitant meds
- 40 patients in SAD – (5, 10, 20, 40mg/kg)
- 40 patients in MAD – (5, 20, 40mg/kg; 20mg/kg BID)
- 8 drug treated & 2 placebo in each cohort

Results

- No drug-related AEs in entire study (up to 7 days treatment)
- No abnormal labs
- Normalization of sorbitol (PD biomarker)

Part C

Design


- 30 DbCM patients
- 10 patients per cohort (8 drug treated, 2 placebo)
 - Placebo
 - 1,500mg BID
 - 1,000mg TID

Results


- No drug-related AEs in entire study (up to 28 days treatment)
- No drug-related lab abnormalities
- Effect on cardiac biomarker NTproBNP

AT-001 Normalizes Sorbitol, a Biomarker of AR Activity, in Diabetic Patients


Proof of Biological Activity



Sorbitol Reduction by Dose



Sorbitol Normalization Over Time




- Drug treatment with AT-001 normalized sorbitol to healthy volunteer levels

- Mean reduction in sorbitol at Day 1 and Day 7: Results are persistent over 1 week of treatment
- At 40mg/kg patients were normalized to healthy volunteer sorbitol levels, demonstrating complete AR inhibition

- Rapid release capsule provides sorbitol normalization effects (PD biomarker) through 10-12hrs post-dose at >10mg/kg
- Includes protection from food-related sorbitol spikes during times of post-prandial hyperglycemia


NTproBNP Levels are Elevated in DbCM Patients (Blood-based cardiac stress biomarker)



References: Kosmala et al, JACC V O L . 6 5 , NO . 3 , 20 1 5; Swank et al. Circ HF 2012; Wang et al. JACC: Cardiovasc Imaging 2018; From et al. JACC 2010


AT-001 Reduced Levels of NTproBNP Cardiac Stress Biomarker Over 28 Days of Treatment

Sorbitol Normalization




- Significant sorbitol reduction achieved by both 1,000mg TID and 1,500mg BID AT-001
- Higher C_{max} achieved with BID slightly beneficial – normalizes sorbitol to healthy volunteer levels

Mean Reduction in NTproBNP



- Mean reduction in NTproBNP seen over 28 days vs. placebo
 - Mean baseline NTproBNP was 65pg/ml


Clinical Responder Analysis



- ~50% AT-001 treated patients demonstrated a clinically meaningful reduction in NTproBNP over 28 days
 - >25pg/ml reduction from baseline

DbCM Phase 3 Registrational Study (ARISE-HF)

Randomized, Placebo-Controlled Study in DbCM Patients at High Risk of Progression




Appendix / Backup Slides

Addressing Large Indications in Areas of High Unmet Medical Need – Opportunities for Abbreviated Clinical Development

Indication	Prevalence	Market	Unmet Need	Development Strategy
Diabetic Cardiomyopathy	17-24% Diabetics	~77M patients worldwide	<ul style="list-style-type: none"> No therapies approved No known drugs in development Entresto approved in stage 4 disease 	Independent; Abbreviated Development
Retinopathy	35% Diabetics	~158M patients worldwide	<ul style="list-style-type: none"> 2 therapies approved (intravitreal injection) Anti-VEGFs only for late stage disease 	Independent; Abbreviated Development
Diabetic Peripheral Neuropathy	50% Diabetics	~226M patients worldwide	<ul style="list-style-type: none"> No disease-modifying therapies approved Only symptomatic treatments available (Lyrica) Epalrestat, an off-patent ARI, approved in Japan, China, India 	Strategic Partner; Standard Development
Galactosemia	1/50k to 1/90k	~2,800 patients in the US	<ul style="list-style-type: none"> No therapies approved; lactose dietary restriction not sufficient No known drugs in development 	Independent; Abbreviated Development (includes PRV)

Novel Chemistry For Better Drugs

Backbone



zopolrestat


Similar backbone to zopolrestat (prior best in class efficacy, but liver tox issues)

Technological Advancements


- Advanced crystallography provided novel understanding of structural changes within AR active site
- Many prior ARIs were unable to inhibit redox-activated AR

Impact of Modified Structure


- Functional modifications improve compound's binding affinity and specificity
- Novel dimeric binding within the catalytic core
- Higher enzymatic inhibitory activity
- Increased selectivity leads to less off-target activity and potentially better safety



AT-001



AT-007




AT-003

Intellectual Property Summary

- Dominant IP and Freedom to Operate on all compounds & all target indications
- Expected IP runway of at least 10 years post-launch in key indications
- Composition of matter patents that cover AT-001 and related compounds obtained US, EP, JP, CA and AU
 - Patent protection through 2031, regulatory extension of term possible
 - Method claims obtained or currently being pursued
- Composition of matter patent that covers AT-007 and related compounds obtained in US
 - Pending on fast track in Europe, pending in other countries
- Company-owned international applications (PCT) cover methods for treating Galactosemia and additional compound derivatives

If Blocking AR Doesn't Increase Galactose or Gal-1P..... Where Does the Extra Substrate Go?



Diabetic Peripheral Neuropathy

Burden of Disease

- Aldose Reductase activity in neurons causes osmotic dysregulation and cell death/neuronal dysfunction
- Tingling/burning/stinging sensation and loss of feeling in peripheral tissues
- Significant impact on quality of life and pharmacoeconomic metrics (ability to work)

Standard of Care

- No disease modifying therapies approved
- Epalrestat (ARI) approved for 20+ years in Japan: dosed 3-5x/day; numerous side effects
- Standard of care outside of Japan/China is analgesic (pain) management, primarily Lyrica

Building on Prior Body of Evidence

- Epalrestat is understood to be safe and moderately effective, but unfavorable PK profile (5X daily dosing)
- Never approved in US/EU; now generic in Japan/China
- Phase 4 trials in Japan demonstrated statistical effects on MNCV and symptomatic pain (Hotta et al)

Current Phase 1 SAD/MAD Trial

- Current AT-001 Phase 1 results show favorable PK vs. Epalrestat
- DPN metrics (MNCV) will be captured in Phase 2/3 pivotal Diabetic Cardiomyopathy trial
- Demonstrate POC for AT-001 in DPN and inform on dose selection for registrational DPN trials

Future Path to Registration

- Will require “typical” path to registration
 - 2 large Phase 3 trials
- Design will follow Epalrestat Phase 4 trials– careful selection of patient population and performance of endpoint testing
- Likely to pursue strategic partnership with large pharmaceutical company

AT-003 for Diabetic Retinopathy

Burden of Disease

- One of the major causes of blindness worldwide
- Current therapies (anti-VEGFs) are high cost biologics that require intravitreal administration by an ophthalmologist
- Limited access for patients and high economic burden
- AR is an upstream target vs. VEGF – opportunity to blunt damage to the eye at the earliest stages

Building on Prior Body of Evidence

- Clear proof of mechanism: AR activation / increased sorbitol as the initial pathogenesis of retinopathy is well supported
- Sorbitol build up in the lens causes osmotic dysregulation
- AR knock-out mice do not develop diabetic retinopathy; AR over-expressing mice develop retinopathy earlier than WT
- 2 prior ARIs met endpoints in Phase 2 trials, but were toxic

Standard of Care

- Current treatments (anti-VEGF therapies) target downstream consequences of diabetic complications in the eye
- Lucentis & Eylea are leading approved therapies for DME; limited to treating later stage / more severe stages of disease

AT-003 in Preclinical Development


- Proof-of-concept in animal models of retinopathy
- AT-003 displays a similar PK to AT-001, but has greater retinal penetrance
- IND-enabling studies and manufacturing scale up are under way

Anticipated Changes in Functional Capacity and Progression to Overt Heart Failure in Study Population

Anticipated mean baseline functional capacity (Peak VO₂) <6 METS (21ml/kg/min) represents a steep slope of decline and strong relationship between changes in functional capacity and ability to perform everyday tasks

	Peak VO ₂	Metabolic 'Cost' of Activity
Light and moderate intensity	3.5	Rest
	7.0-10.5	Walking 2mph, eating, dressing
	14.0-17.5	Walking 4mph, household tasks
Vigorous intensity	21.0-24.5	Walking up stairs, Stage 2 Bruce: 2.5mph, 12%
	28.0-31.5	Swimming, tennis
	35.0-38.5	Jogging 10 min/miles, Stage 3 Bruce: 3.4mph, 14%
	42.0-49.0	Intense aerobic sports, squash Stage 4 Bruce: 4.2mph, 16%
	>70.0	Professional athletes/Olympians

Progression to Overt Heart Failure



AMA Guides to the Evaluation of Permanent Impairment, Sixth Edition. Author: Robert D. Rondonelli, MD, PhD

Wang Y, Marwick TH. JACC: CV Imaging 2018